Results 301 to 310 of about 2,534,599 (334)

Monoclonal Antibodies

2009
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire   +2 more sources

An Overview of Monoclonal Antibodies

Seminars in Oncology Nursing, 2019
To provide a brief overview of the development of monoclonal antibodies in immunotherapy, including a review of the mechanism of action and types, and indications for use.Peer-reviewed journal articles, book chapters, internet.Monoclonal antibodies offer alternative treatment to cancer patients who have failed or progressed on standard chemotherapy ...
openaire   +2 more sources

Generating Monoclonal Antibodies

Cold Spring Harbor Protocols, 2022
Antibodies that are produced by hybridomas are known as monoclonal antibodies. Here we introduce methods for generating and screening monoclonal antibodies, including developing the screening procedure and producing hybridomas.
openaire   +2 more sources

Monoclonal antibodies in oncology

Radiotherapy and Oncology, 1986
Monoclonal antibodies (MCAs) can be used to differentiate between normal and neoplastic cells and thus exploited for diagnostic and, ultimately, therapeutic gain. The evidence for the existence of human tumour antigens is reviewed. Several areas of diagnosis are already benefiting from the application of the monoclonal technology.
S Y, Chan, K, Sikora
openaire   +2 more sources

Monoclonal antibodies in myeloma.

Clinical advances in hematology & oncology : H&O, 2015
The development of monoclonal antibodies (mAbs) for the treatment of disease goes back to the vision of Paul Ehrlich in the late 19th century; however, the first successful treatment with a mAb was not until 1982, in a lymphoma patient. In multiple myeloma, mAbs are a very recent and exciting addition to the therapeutic armamentarium. The incorporation
Sondergeld, P., van de Donk, N. W. C. J., Richardson, P. G., Plesner, T.   +3 more
openaire   +5 more sources

Monoclonal Antibodies to Benzodiazepines

Journal of Neurochemistry, 1985
Abstract: Four hybridoma lines secreting monoclonal antibodies to benzodiazepines were produced after BALB/c mice were immunized with a benzodiazepine‐bovine serum albumin conjugate. The monoclonal antibodies were purified from ascites fluids, and their binding affinities for benzodiazepines and other benzodiazepine receptor ligands were determined ...
A L, De Blas, L, Sangameswaran, S A, Haney, D, Park, C J, Abraham, C A, Rayner   +5 more
openaire   +2 more sources

Monoclonal antibodies to transthyretin

Scandinavian Journal of Clinical and Laboratory Investigation, 1986
Monoclonal antibodies (mabs) have been raised against human transthyretin (hTTR). The protein was isolated by an affinity chromatography procedure using Sepharose-hRBP and BALB/c mice were immunized. Following fusion with SP 2/0 myeloma cells, 26 single cell clones producing antibodies against hTTR were isolated.
V P, Collins, B, Jacobsson, T, Pettersson, A, Carlström   +3 more
openaire   +2 more sources

Antibodies: monoclonal and polyclonal

Animal Biotechnology, 2020
Anchal Singh, Ayushi Mishra, Anju Verma
semanticscholar   +1 more source

ANTIRETINOBLASTOMA MONOCLONAL ANTIBODIES

Retina, 1983
Mouse-mouse somatic hybridization techniques were used to produce monoclonal antibodies directed towards antigen expressed on retinoblastoma-derived tissue culture cell lines. Four monoclonal antibodies were produced with varying avidity which were reactive against allogeneic retinoblastoma-associated antigens.
D H, Char, N, Rand, E L, Howes, H, Lyon, C T, Morita   +4 more
openaire   +2 more sources

Deimmunization of Monoclonal Antibodies

2008
Immunogenicity is a major limitation to therapy with certain monoclonal antibodies and proteins. A major driver for immunogenicity is the presence of human T-cell epitopes within the protein sequence which can activate helper T-cells resulting in the sustained production of antibodies and neutralization of the therapeutic effect.
Tim D, Jones, Laura J, Crompton, Frank J, Carr, Matthew P, Baker   +3 more
openaire   +2 more sources